Inhibition of mitogen-activated protein kinase 1/2 in the acute phase of stroke improves long-term neurological outcome and promotes recovery processes in rats.

Maryam Mostajeran; Lars Edvinsson; Karin Warfvinge; Rushani Singh; Saema Ansar

doi:10.1111/apha.12632

Inhibition of mitogen-activated protein kinase 1/2 in the acute phase of stroke improves long-term neurological outcome and promotes recovery processes in rats.

Maryam Mostajeran, Lars Edvinsson, Karin Warfvinge, Rushani Singh, Saema Ansar

Experimental Vascular Research

Lund University

Research output: Contribution to journal › Article › peer-review

Abstract

Extracellular signal-regulated kinase (ERK) 1/2 is activated during acute phase of stroke and contributes to stroke pathology. We have found that acute treatment with MEK1/2 inhibitors decrease infarct size and neurological deficits two days after experimental stroke. However it is not known whether benefits of this inhibition persist long-term. Therefore, the aim of this study was to assess neurological function, infarct size and recovery processes 14 days after stroke in male rats to determine long-term outcome following acute treatment with the MEK1/2 inhibitor U0126.

Original language	English
Journal	Acta Physiologica
Early online date	2015 Nov 23
DOIs	https://doi.org/10.1111/apha.12632
Publication status	Published - 2015

Subject classification (UKÄ)

Neurology

Access to Document

10.1111/apha.12632

http://www.ncbi.nlm.nih.gov/pubmed/26595054?dopt=Abstract

1 Doctoral Thesis (compilation)

A Path for Improving Stroke Recovery. Effects of MEK-ERK1/2 Inhibition
Mostajeran, M., 2018, Lund: Lund University: Faculty of Medicine. 70 p.
Research output: Thesis › Doctoral Thesis (compilation)

Open Access
File

Cite this

@article{948cb383d36b4160881db1d7ffa7d788,

title = "Inhibition of mitogen-activated protein kinase 1/2 in the acute phase of stroke improves long-term neurological outcome and promotes recovery processes in rats.",

abstract = "Extracellular signal-regulated kinase (ERK) 1/2 is activated during acute phase of stroke and contributes to stroke pathology. We have found that acute treatment with MEK1/2 inhibitors decrease infarct size and neurological deficits two days after experimental stroke. However it is not known whether benefits of this inhibition persist long-term. Therefore, the aim of this study was to assess neurological function, infarct size and recovery processes 14 days after stroke in male rats to determine long-term outcome following acute treatment with the MEK1/2 inhibitor U0126.",

author = "Maryam Mostajeran and Lars Edvinsson and Karin Warfvinge and Rushani Singh and Saema Ansar",

year = "2015",

doi = "10.1111/apha.12632",

language = "English",

journal = "Acta Physiologica",

issn = "1748-1716",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Inhibition of mitogen-activated protein kinase 1/2 in the acute phase of stroke improves long-term neurological outcome and promotes recovery processes in rats.

AU - Mostajeran, Maryam

AU - Edvinsson, Lars

AU - Warfvinge, Karin

AU - Singh, Rushani

AU - Ansar, Saema

PY - 2015

Y1 - 2015

N2 - Extracellular signal-regulated kinase (ERK) 1/2 is activated during acute phase of stroke and contributes to stroke pathology. We have found that acute treatment with MEK1/2 inhibitors decrease infarct size and neurological deficits two days after experimental stroke. However it is not known whether benefits of this inhibition persist long-term. Therefore, the aim of this study was to assess neurological function, infarct size and recovery processes 14 days after stroke in male rats to determine long-term outcome following acute treatment with the MEK1/2 inhibitor U0126.

AB - Extracellular signal-regulated kinase (ERK) 1/2 is activated during acute phase of stroke and contributes to stroke pathology. We have found that acute treatment with MEK1/2 inhibitors decrease infarct size and neurological deficits two days after experimental stroke. However it is not known whether benefits of this inhibition persist long-term. Therefore, the aim of this study was to assess neurological function, infarct size and recovery processes 14 days after stroke in male rats to determine long-term outcome following acute treatment with the MEK1/2 inhibitor U0126.

U2 - 10.1111/apha.12632

DO - 10.1111/apha.12632

M3 - Article

C2 - 26595054

SN - 1748-1716

JO - Acta Physiologica

JF - Acta Physiologica

ER -

Inhibition of mitogen-activated protein kinase 1/2 in the acute phase of stroke improves long-term neurological outcome and promotes recovery processes in rats.

Abstract

Subject classification (UKÄ)

Access to Document

Fingerprint

Research output

A Path for Improving Stroke Recovery. Effects of MEK-ERK1/2 Inhibition

Cite this